1-19 of 19
Maher Albitar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma

Zijun Y. Xu-Monette, Li Wei, Xiaosheng Fang, Qingyan Au, Harry Nunns, Máté Nagy, Alexandar Tzankov, Feng Zhu, Carlo Visco, Govind Bhagat, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, Fredrick B. Hagemeister, Xiaoping Sun, Xin Han, Heounjeong Go, Maurilio Ponzoni, Andrés J.M. Ferreri, Michael B. Møller, Benjamin M. Parsons, J. Han van Krieken, Miguel A. Piris, Jane N. Winter, Yong Li, Bing Xu, Maher Albitar, Hua You, Ken H. Young
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 972–983.
https://doi.org/10.1158/1078-0432.CCR-21-2949
Published: 03 March 2022
View article titled, Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma
Open the PDF for Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Enzymatic activity of free circulating proteasomes as biomarkers for predicting clinical behavior in hematologic diseases

Maher Albitar, Wanlong Ma, Susan O'Brien, Iman Jilani, Xi Zhang, Hagop Kantarjian, Zeev Estrov, Michael Keating, Francis Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): B52.
Published: 15 August 2014
View article titled, Enzymatic activity of free circulating proteasomes as biomarkers for predicting clinical behavior in hematologic diseases
Journal Articles

BCR-ABL alternative-splicing as a common mechanism for Imatinib resistance: Evidence from molecular dynamics simulations

Wanlong Ma, Tai-Sung Lee, Xi Zhang, Geoge Cortes, Francis Giles, Hagop Kantarjian, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15_Supplement): B31.
Published: 15 August 2014
View article titled, BCR-ABL alternative-splicing as a common mechanism for Imatinib resistance: Evidence from molecular dynamics simulations
Journal Articles

Plasma is more sensitive than cellular analysis for detecting JAK2 mutations and determining zygosity

Maher Albitar, Wanlong Ma, Xi Zhang, Iman Jilani, Hagop Kantarjian, Francis Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): B53.
Published: 15 August 2014
View article titled, Plasma is more sensitive than cellular analysis for detecting <em>JAK2</em> mutations and determining zygosity
Journal Articles

Mutation profile of JAK2 gene in patients with chronic myeloproliferative neoplasias

Wanlong Ma, Hagop Kantarjian, Xi Zhang, Chen-Hsiung Yeh, Zhong Zhang, Srdan Verstovsek, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19_Supplement): B12.
Published: 15 August 2014
View article titled, Mutation profile of JAK2 gene in patients with chronic myeloproliferative neoplasias
Journal Articles

Clinical relevance of circulating heat shock protein 70 in acute leukemias

Chen-Hsiung Yeh, Richard Tseng, Susan O'Brien, Alison Hannah, Zeev Estrov, Elihu Estey, Hagop Kantarjian, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19_Supplement): B13.
Published: 15 August 2014
View article titled, Clinical relevance of circulating heat shock protein 70 in acute leukemias
Journal Articles

Circulating Ki-67 protein as a biomarker and prognostic indicator of acute lymphoblastic leukemia

Jean-Marie Bruey, Hagop Kantarjian, Wanlong Ma, Deborah Thomas, Francis Giles, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19_Supplement): B36.
Published: 15 August 2014
View article titled, Circulating Ki-67 protein as a biomarker and prognostic indicator of acute lymphoblastic leukemia
Journal Articles

Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome

Wanlong Ma, Hagop Kantarjian, Benjamin Bekele, Amber C. Donahue, Xi Zhang, Zhong J. Zhang, Susan O'Brien, Elihu Estey, Zeev Estrov, Jorge Cortes, Michael Keating, Francis Giles, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (11): 3820–3826.
https://doi.org/10.1158/1078-0432.CCR-08-3034
Published: 01 June 2009
View article titled, Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome
Open the PDF for Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome in another window
Includes: Supplementary data
Journal Articles

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

David A. Rizzieri, Eric Feldman, John F. DiPersio, Nashat Gabrail, Wendy Stock, Roger Strair, Victor M. Rivera, Maher Albitar, Camille L. Bedrosian, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2756–2762.
https://doi.org/10.1158/1078-0432.CCR-07-1372
Published: 01 May 2008
View article titled, A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies in another window
Journal Articles

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

Karen W.L. Yee, Zhihong Zeng, Marina Konopleva, Srdan Verstovsek, Farhad Ravandi, Alessandra Ferrajoli, Deborah Thomas, William Wierda, Efrosyni Apostolidou, Maher Albitar, Susan O'Brien, Michael Andreeff, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5165–5173.
https://doi.org/10.1158/1078-0432.CCR-06-0764
Published: 01 September 2006
View article titled, Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies in another window
Journal Articles

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

Francis Giles, Thomas Fischer, Jorge Cortes, Guillermo Garcia-Manero, Joachim Beck, Farhad Ravandi, Eric Masson, Patricia Rae, Glen Laird, Sunil Sharma, Hagop Kantarjian, Margaret Dugan, Maher Albitar, Kapil Bhalla
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4628–4635.
https://doi.org/10.1158/1078-0432.CCR-06-0511
Published: 09 August 2006
View article titled, A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies
Open the PDF for A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies in another window
Journal Articles

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

Francis Giles, Srdan Verstovsek, Deborah Thomas, Stanton Gerson, Jorge Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven Kornblau, Guillermo Garcia-Manero, Elias Jabbour, Susan O'Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7817–7824.
https://doi.org/10.1158/1078-0432.CCR-05-1070
Published: 08 November 2005
View article titled, Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Open the PDF for Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia in another window
Journal Articles

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Karen W.L. Yee, Anne Hagey, Srdan Verstovsek, Jorge Cortes, Guillermo Garcia-Manero, Susan M. O'Brien, Stefan Faderl, Deborah Thomas, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Maher Albitar, Evelyn McKeegan, David R. Grimm, Toby Mueller, Rhonda R. Holley-Shanks, Leonardo Sahelijo, Gary B. Gordon, Hagop M. Kantarjian, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6615–6624.
https://doi.org/10.1158/1078-0432.CCR-05-0650
Published: 15 September 2005
View article titled, Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies
Open the PDF for Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies in another window
Journal Articles

Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma

Maurizio Zangari, Elias Anaissie, Alison Stopeck, Alyssa Morimoto, Nguyen Tan, Jeffrey Lancet, Maureen Cooper, Alison Hannah, Guillermo Garcia-Manero, Stephan Faderl, Hagop Kantarjian, Julie Cherrington, Maher Albitar, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 88–95.
https://doi.org/10.1158/1078-0432.CCR-0221-3
Published: 20 January 2004
View article titled, Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma
Open the PDF for Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma in another window
Journal Articles

Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α: Follow-Up Results

Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Terry L. Smith, Francis J. Giles, Stefan Faderl, Deborah A. Thomas, Guillermo Garcia-Manero, Jean-Pierre J. Issa, Michael Andreeff, Steven M. Kornblau, Charles Koller, Milosav Beran, Michael Keating, Mary Beth Rios, Jenny Shan, Debra Resta, Renaud Capdeville, Kimberly Hayes, Maher Albitar, Emil J. Freireich, Jorge E. Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (7): 2177–2187.
Published: 01 July 2002
View article titled, Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α: <subtitle>Follow-Up Results</subtitle>
Open the PDF for Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α: <subtitle>Follow-Up Results</subtitle> in another window
Journal Articles

High Levels of Vascular Endothelial Growth Factor Receptor-2 Correlate with Shortened Survival in Chronic Lymphocytic Leukemia

Alessandra Ferrajoli, Taghi Manshouri, Zeev Estrov, Michael J. Keating, Susan O’Brien, Susan Lerner, Miloslav Beran, Hagop M. Kantarjian, Emil J. Freireich, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (4): 795–799.
Published: 01 April 2001
View article titled, High Levels of Vascular Endothelial Growth Factor Receptor-2 Correlate with Shortened Survival in Chronic Lymphocytic Leukemia
Open the PDF for High Levels of Vascular Endothelial Growth Factor Receptor-2 Correlate with Shortened Survival in Chronic Lymphocytic Leukemia in another window
Journal Articles

Significance of FHIT Expression in Chronic Myelogenous Leukemia

Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Taghi Manshouri, Jorge Cortes, Francis Giles, Mary Beth Rios, Carlo M. Croce, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (12): 4059–4064.
Published: 01 December 1999
View article titled, Significance of FHIT Expression in Chronic Myelogenous Leukemia
Open the PDF for Significance of FHIT Expression in Chronic Myelogenous Leukemia in another window
Journal Articles

Loss of FHIT Expression in Acute Lymphoblastic Leukemia

Cora Hallas, Maher Albitar, Jean Letofsky, Michael J. Keating, Kay Huebner, Carlo M. Croce
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (9): 2409–2414.
Published: 01 September 1999
View article titled, Loss of <em>FHIT</em> Expression in Acute Lymphoblastic Leukemia
Open the PDF for Loss of <em>FHIT</em> Expression in Acute Lymphoblastic Leukemia in another window
Journal Articles

The Prognostic Significance of p16INK4a/p14ARF and p15INK4b Deletions in Adult Acute Lymphoblastic Leukemia

Stefan Faderl, Hagop M. Kantarjian, Taghi Manshouri, Chin-Yung Chan, Sherry Pierce, Kimberly J. Hays, Jorge Cortes, Deborah Thomas, Zeev Estrov, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (7): 1855–1861.
Published: 01 July 1999
View article titled, The Prognostic Significance of <em>p16</em><sup><em>INK4a</em></sup>/<em>p14</em><sup><em>ARF</em></sup> and <em>p15</em><sup><em>INK4b</em></sup> Deletions in Adult Acute Lymphoblastic Leukemia
Open the PDF for The Prognostic Significance of <em>p16</em><sup><em>INK4a</em></sup>/<em>p14</em><sup><em>ARF</em></sup> and <em>p15</em><sup><em>INK4b</em></sup> Deletions in Adult Acute Lymphoblastic Leukemia in another window